Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-16 5:04 pm Sale |
2020-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM |
Baker Bros. Advisors LP | 2,314,873 5.200% |
-393,327 (-14.52%) |
Filing History |
| 2021-02-16 4:58 pm Purchase |
2020-12-31 | 13G | Madrigal Pharmaceuticals, Inc. MDGL |
Baker Bros. Advisors LP | 1,499,213 9.700% |
329,935 (+28.22%) |
Filing History |
| 2021-02-16 4:58 pm Purchase |
2021-02-16 | 13G | Immunocore Holdings plc IMCR |
Baker Bros. Advisors LP | 3,352,357 7.500% |
3,352,357 (New Position) |
Filing History |
| 2021-02-16 4:53 pm Purchase |
2020-12-31 | 13G | Mereo BioPharma Group plc MREO |
Baker Bros. Advisors LP | 39,631,929 11.400% |
39,631,929 (New Position) |
Filing History |
| 2021-02-16 4:53 pm Purchase |
2020-12-31 | 13G | Amarin Corporation plc AMRN |
Baker Bros. Advisors LP | 28,115,133 7.200% |
5,445,624 (+24.02%) |
Filing History |
| 2021-02-16 4:53 pm Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 195,701 9.900% |
127,157 (+185.51%) |
Filing History |
| 2021-02-16 4:53 pm Purchase |
2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Baker Bros. Advisors LP | 18,178,881 9.990% |
2,303,756 (+14.51%) |
Filing History |
| 2021-02-16 4:50 pm Sale |
2020-12-31 | 13G | InflaRx N.V. IFRX |
Baker Bros. Advisors LP | 856,228 3.000% |
-922,187 (-51.85%) |
Filing History |
| 2021-02-16 4:40 pm Purchase |
2020-12-31 | 13G | Opthea Limited OPT |
Baker Bros. Advisors LP | 33,963,240 9.800% |
33,963,240 (New Position) |
Filing History |
| 2021-02-16 4:35 pm Purchase |
2020-12-31 | 13G | Cerus Corporation CERS |
Baker Bros. Advisors LP | 13,733,059 8.200% |
2,963,258 (+27.51%) |
Filing History |
| 2021-02-16 4:27 pm Sale |
2020-12-31 | 13G | Krystal Biotech, Inc. KRYS |
Baker Bros. Advisors LP | 698,874 3.500% |
-335,800 (-32.45%) |
Filing History |
| 2021-02-16 4:22 pm Purchase |
2020-12-31 | 13G | Altimmune, Inc. ALT |
Baker Bros. Advisors LP | 1,884,451 5.100% |
1,884,451 (New Position) |
Filing History |
| 2021-02-16 4:16 pm Purchase |
2020-12-31 | 13G | Verastem, Inc. VSTM |
Baker Bros. Advisors LP | 845,337 6.000% |
845,337 (New Position) |
Filing History |
| 2021-02-16 4:08 pm Purchase |
2020-12-31 | 13G | Adaptimmune Therapeutics plc ADAP |
Baker Bros. Advisors LP | 58,985,262 6.400% |
58,985,262 (New Position) |
Filing History |
| 2021-02-05 4:53 pm Unchanged |
2021-02-05 | 13G | Zymeworks Inc. ZYME |
Baker Bros. Advisors LP | 4,909,810 9.990% |
0 (Unchanged) |
Filing History |
| 2021-01-29 5:03 pm Purchase |
2021-01-23 | 13D | IGM Biosciences, Inc. IGMS |
Baker Bros. Advisors LP | 3,157,784 12.400% |
513 (+0.02%) |
Filing History |
| 2021-01-29 4:55 pm Purchase |
2021-01-25 | 13D | Zymeworks Inc. ZYME |
Baker Bros. Advisors LP | 4,909,810 9.990% |
47,396 (+0.97%) |
Filing History |
| 2021-01-29 4:48 pm Purchase |
2021-01-22 | 13D | Prelude Therapeutics Incorporated PRLD |
Baker Bros. Advisors LP | 10,126,417 28.800% |
5,189 (+0.05%) |
Filing History |
| 2021-01-29 4:38 pm Sale |
2020-12-31 | 13G | Idera Pharmaceuticals, Inc. IDRA |
Baker Bros. Advisors LP | 546,037 12.100% |
-6,446 (-1.17%) |
Filing History |
| 2021-01-05 5:14 pm Sale |
2021-01-05 | 13D | IGM Biosciences, Inc. IGMS |
Baker Bros. Advisors LP | 3,157,271 12.400% |
-35,751 (-1.12%) |
Filing History |